A. Chanan-Khan Et Al. , "Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab," 57th Annual Meeting of the American-Society-of-Hematology , vol.126, Florida, United States Of America, 2015
Chanan-Khan, A. Et Al. 2015. Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. 57th Annual Meeting of the American-Society-of-Hematology , (Florida, United States Of America).
Chanan-Khan, A., Cramer, P., DEMİRKAN, F., Fraser, G., Silva, R. S., Pylypenko, H., ... Grosicki, S.(2015). Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab . 57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America
Chanan-Khan, Asher Et Al. "Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab," 57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 2015
Chanan-Khan, Asher Et Al. "Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab." 57th Annual Meeting of the American-Society-of-Hematology , Florida, United States Of America, 2015
Chanan-Khan, A. Et Al. (2015) . "Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab." 57th Annual Meeting of the American-Society-of-Hematology , Florida, United States Of America.
@conferencepaper{conferencepaper, author={Asher Chanan-Khan Et Al. }, title={Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab}, congress name={57th Annual Meeting of the American-Society-of-Hematology}, city={Florida}, country={United States Of America}, year={2015}}